See the DrugPatentWatch profile for Turalio
What is Turalio and what is it used for?
Turalio is an oral therapy (capsules) that contains the active ingredient pexidartinib. It is used to treat adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and where surgery is not an option or is likely to cause severe complications.
How does Turalio work as a targeted oral cancer drug?
Pexidartinib is a targeted inhibitor of CSF1R (colony-stimulating factor 1 receptor). TGCT is driven in part by CSF1R signaling in tumor and immune-cell interactions, and blocking CSF1R helps reduce tumor activity in patients who cannot safely undergo surgery.
How is Turalio taken (oral therapy details)?
Turalio is taken by mouth as an oral capsule therapy. The exact dosing schedule (dose and days on treatment versus off treatment) depends on the prescribing regimen and patient factors such as tolerability and liver function.
What safety issues matter most for people taking Turalio?
The main safety concern for Turalio is liver injury (hepatotoxicity), so liver tests are typically monitored during treatment. Other adverse effects can include issues like taste changes, fatigue, swelling, and nausea, depending on the individual.
Why is Turalio considered when surgery isn’t possible?
TGCT can sometimes be difficult to resect completely, or surgery can carry high risk of lasting disability or severe complications. In those situations, a targeted systemic therapy like pexidartinib can be used to control symptoms and tumor burden when surgery is not feasible.
Does Turalio have a patent/exclusivity history?
DrugPatentWatch.com tracks patents and market exclusivity for branded drugs and can be useful for checking Turalio-related legal status and timeline questions. You can search Turalio/pexidartinib on DrugPatentWatch for the latest patent and exclusivity details: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/